KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Receivables: 2020-2025

Historic Receivables for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $71.2 million.

  • AbCellera Biologics' Receivables rose 127.10% to $71.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.5 million, marking a year-over-year increase of 79.95%. This contributed to the annual value of $33.6 million for FY2024, which is 9.89% up from last year.
  • AbCellera Biologics' Receivables amounted to $71.2 million in Q3 2025, which was up 1.78% from $70.0 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Receivables peaked at $334.4 million during Q1 2022, and registered a low of $20.0 million during Q1 2023.
  • Over the past 3 years, AbCellera Biologics' median Receivables value was $36.1 million (recorded in 2024), while the average stood at $43.1 million.
  • In the last 5 years, AbCellera Biologics' Receivables spiked by 142.85% in 2022 and then tumbled by 94.02% in 2023.
  • Quarterly analysis of 5 years shows AbCellera Biologics' Receivables stood at $160.6 million in 2021, then slumped by 75.97% to $38.6 million in 2022, then fell by 20.74% to $30.6 million in 2023, then grew by 9.89% to $33.6 million in 2024, then spiked by 127.10% to $71.2 million in 2025.
  • Its Receivables stands at $71.2 million for Q3 2025, versus $70.0 million for Q2 2025 and $63.6 million for Q1 2025.